Anti-Mullerian Hormone Changes After Laparoscopic Ovarian Cystectomy for Endometrioma Compared With the Non-ovarian Conditions

Ovarian Reserve Clinical Trial

Clinical Trial Details — Status: Unknown status

Administrative data

• NCT number: NCT01919333
• Other study ID #: MTU-OB-3-096/56
• Status: Unknown status
• Phase: Phase 3
• First received: August 6, 2013
• Last updated: August 6, 2013
• Start date: December 2012

Study information

• Verified date: August 2013
• Source: Thammasat University
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This aim of the study is to evaluate the impact of endometrioma and laparoscopic cystectomy on ovarian reserve as measured by serum antimullerian hormone and to study the different effects of levels of serum antimullerian hormone between laparoscopic cystectomy and the non-ovarian pelvic surgery.

Recruitment information / eligibility

• Status: Unknown status
• Enrollment: 56
• Est. primary completion date: December 2013
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Female
• Age group: 18 Years to 45 Years

Eligibility

Inclusion Criteria:

• • Participants must be between the ages of 18 - 45 during enter the study .

• Every participants have to completely understand the process of this study and have written informed consent .

• Having regular menstrual cycles (21-35 days) at the time of operation

• no evidence of any other endocrine disorders such as diabetes mellitus, thyroid dysfunction, hyperprolactinemia, congenital adrenal hyperplasia, Cushing's syndrome, or adrenal insufficiency.

• undergo laparoscopic ovarian cystectomy or laparoscopic non- ovarian pelvic surgery for benign pelvic disease

• No previous history of adnexal surgery

• No any suspicious findings of malignant ovarian diseases

• Never taking any medication such as oral pill and hormonal drugs within 3 months before the enrollment.

• pathological diagnosis of excised ovarian tissue confirm as endometriotic cyst in study group and other benign pelvic disease in control group

Exclusion Criteria:

• polycystic ovarian syndrome according to the Rotterdam criteria

• pathological report as the malignant diseases

• have operation conversion to open-laparotomy

Related Conditions & MeSH terms

• Ovarian Reserve

Locations

Country	Name	City	State
Thailand	Faculty of medicine , Thammasat university	Rangsit	Pathumthanee

Sponsors (1)

Lead Sponsor	Collaborator
Thammasat University

Country where clinical trial is conducted

Thailand, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Serum AMH levels		6 months